



TO BE RELEASED February 21, 2006 – 3 p.m.

# Communiqué

## The PMPRB Will Hold a Public Hearing into the Price of Airomir

OTTAWA, **February 21, 2006**: The Patented Medicine Prices Review Board has scheduled a pre-hearing conference for May 19, 2006, in the matter of 3M Canada Company (3M Canada), and the price of the medicine Airomir. The public hearing will start on July 10, 2006.

The purpose of the hearing is to determine whether, under sections 83 and 85 of the *Patent Act*, 3M Canada

- is selling or has sold Airomir in any market in Canada at a price that, in the Board's opinion, is or was excessive; and,
- if so, what order, if any, should be made.

Airomir is used for the treatment of asthma, chronic bronchitis, and other breathing disorders.

Persons wishing to intervene in these proceedings are required to apply to the Board for leave to intervene **on or before March 17, 2006**, by contacting the Secretary of the Board.

The Notice of Hearing in this matter and the Statement of Allegations of Board Staff (severed version) are available on the PMPRB Web site under Publications; Hearings.

All requests for information on this matter and on the Board's procedures should be addressed to the Secretary of the Board.

---

Sylvie Dupont  
Secretary of the Patented Medicine Prices Review Board  
Toll-free number: 1-877-861-2350  
Direct line: (613) 954-8299  
Fax: (613) 952-7626  
E-mail: [sdupont@pmprb-cepmb.gc.ca](mailto:sdupont@pmprb-cepmb.gc.ca)